Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer

被引：2
|
作者：
Kowalczyk, Lidia [1 ]
Singer, Christian F. [2 ]
Staudigl, Christine [2 ]
Weber, Myriam [2 ]
Farr, Alex [2 ]
机构：
[1] Univ Vet Med, Clin Unit Anesthesiol & Perioperat Intens Care Me, Vienna, Austria
[2] Med Univ Vienna, Dept Obstet & Gynecol, Ctr Breast Hlth, Waehringer Guertel 18-20, A-1090 Vienna, Austria
来源：
BREAST JOURNAL | 2017年 / 23卷 / 03期
关键词：
D O I：
10.1111/tbj.12676
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 353
页数：2
相关论文
共 50 条
  • [31] Margetuximab in HER2-positive metastatic breast cancer
    Gradishar, William J.
    O'Regan, Ruth
    Rimawi, Mothaffar F.
    Nordstrom, Jeffrey L.
    Rosales, Minori K.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112
  • [32] Therapy for HER2-Positive Metastatic Breast Cancer
    Dekker, Tim J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [33] Pertuzumab in HER2-positive early breast cancer: current use and perspectives
    Eiger, Daniel
    Ponde, Noam Falbel
    de Azambuja, Evandro
    FUTURE ONCOLOGY, 2019, 15 (16) : 1823 - 1844
  • [34] The role of anthracycline and pertuzumab in preoperative treatment of HER2-positive breast cancer
    Debska-Szmich, Sylwia
    Potemski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (01): : 50 - 58
  • [35] Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients
    Cortes, Javier
    Ciruelos, Eva.
    Perez-Garcia, Jose
    Albanell, Joan
    Garcia-Estevez, Laura
    Ruiz-Borrego, Manuel
    Espinosa, Ruth
    Gallegos, Isabel
    Gonzalez, Santiago
    Alvarez, Isabel
    Llombart, Antonio
    CANCER TREATMENT REVIEWS, 2020, 83
  • [36] Pertuzumab and transtuzumab: Exporatory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer
    Cortes, J.
    Baselga, J.
    Fumoleau, P.
    Gelmon, K. A.
    Ross, G.
    McNally, V.
    Bianchi, G. V.
    Venturi, M.
    Paul, H.
    Gianni, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Al Rabadi, Luai S.
    Cook, Madeline M.
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi, I
    BMC CANCER, 2021, 21 (01)
  • [38] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [39] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    PharmacoEconomics, 2015, 33 : 13 - 23
  • [40] Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
    Okemoto, Dai
    Yamaguchi, Toshifumi
    Yamaguchi, Mariko
    Kadono, Toru
    Yukami, Hiroki
    Fakhrejahani, Elham
    Nishikawa, Hiroki
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 1001 - 1007
12345